The use of absorption enhancers to enhance the despersibility of spray-dried powders for pulmonary gene therapy

Hao-Ying Li, Peter C. Seville, I.J. Williamson, J.C. Birchall

Research output: Contribution to journalArticle

Abstract

Background: Pulmonary gene therapy requires aerosolisation of the gene vectors to the target region of the lower respiratory tract. Pulmonary absorption enhancers have been shown to improve the penetration of pharmaceutically active ingredients in the airway. In this study, we investigate whether certain absorption enhancers may also enhance the aerosolisation properties of spray-dried powders containing non-viral gene vectors. Methods: Spray-drying was used to prepare potentially respirable trehalose-based dry powders containing lipid-polycation-pDNA (LPD) vectors and absorption enhancers. Powder morphology and particle size were characterised using scanning electron microscopy and laser diffraction, respectively, with gel electrophoresis used to assess the structural integrity of the pDNA. The biological functionality of the powders was quantified using in vitro cell (A549) transfection. Aerosolisation from a Spinhaler® dry powder inhaler into a multistage liquid impinger (MSLI) was used to assess the in vitro dispersibility and deposition of the powders. Results: Spray-dried powder containing dimethyl-β-cyclodextrin (DMC) demonstrated substantially altered particle morphology and an optimal particle size distribution for pulmonary delivery. The inclusion of DMC did not adversely affect the structural integrity of the LPD complex and the powder displayed significantly greater transfection efficiency as compared to unmodified powder. All absorption enhancers proffered enhanced powder deposition characteristics, with the DMC-modified powder facilitating high deposition in the lower stages of the MSLI. Conclusions: Incorporation of absorption enhancers into non-viral gene therapy formulations prior to spray-drying can significantly enhance the aerosolisation properties of the resultant powder and increase biological functionality at the site of deposition in an in vitro model. Copyright © 2005 John Wiley & Sons, Ltd.

Original languageEnglish
Pages (from-to)1035-1043
Number of pages9
JournalJournal of Gene Medicine
Volume7
Issue number8
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Genetic Therapy
Powders
Lung
Cyclodextrins
Particle Size
Transfection
Dry Powder Inhalers
Lipids
Metered Dose Inhalers
Trehalose
Transmission Electron Microscopy
Respiratory System
Electron Scanning Microscopy
Genes
Electrophoresis
Lasers
Gels

Keywords

  • absorption enhancer
  • deposition
  • gene delivery
  • lung
  • non-viral
  • spray drying

Cite this

Li, Hao-Ying ; Seville, Peter C. ; Williamson, I.J. ; Birchall, J.C. / The use of absorption enhancers to enhance the despersibility of spray-dried powders for pulmonary gene therapy. In: Journal of Gene Medicine. 2005 ; Vol. 7, No. 8. pp. 1035-1043.
@article{be310baa7f204ea89501255e5e10f6c1,
title = "The use of absorption enhancers to enhance the despersibility of spray-dried powders for pulmonary gene therapy",
abstract = "Background: Pulmonary gene therapy requires aerosolisation of the gene vectors to the target region of the lower respiratory tract. Pulmonary absorption enhancers have been shown to improve the penetration of pharmaceutically active ingredients in the airway. In this study, we investigate whether certain absorption enhancers may also enhance the aerosolisation properties of spray-dried powders containing non-viral gene vectors. Methods: Spray-drying was used to prepare potentially respirable trehalose-based dry powders containing lipid-polycation-pDNA (LPD) vectors and absorption enhancers. Powder morphology and particle size were characterised using scanning electron microscopy and laser diffraction, respectively, with gel electrophoresis used to assess the structural integrity of the pDNA. The biological functionality of the powders was quantified using in vitro cell (A549) transfection. Aerosolisation from a Spinhaler{\circledR} dry powder inhaler into a multistage liquid impinger (MSLI) was used to assess the in vitro dispersibility and deposition of the powders. Results: Spray-dried powder containing dimethyl-β-cyclodextrin (DMC) demonstrated substantially altered particle morphology and an optimal particle size distribution for pulmonary delivery. The inclusion of DMC did not adversely affect the structural integrity of the LPD complex and the powder displayed significantly greater transfection efficiency as compared to unmodified powder. All absorption enhancers proffered enhanced powder deposition characteristics, with the DMC-modified powder facilitating high deposition in the lower stages of the MSLI. Conclusions: Incorporation of absorption enhancers into non-viral gene therapy formulations prior to spray-drying can significantly enhance the aerosolisation properties of the resultant powder and increase biological functionality at the site of deposition in an in vitro model. Copyright {\circledC} 2005 John Wiley & Sons, Ltd.",
keywords = "absorption enhancer, deposition, gene delivery, lung, non-viral, spray drying",
author = "Hao-Ying Li and Seville, {Peter C.} and I.J. Williamson and J.C. Birchall",
year = "2005",
month = "8",
doi = "10.1002/jgm.749",
language = "English",
volume = "7",
pages = "1035--1043",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

The use of absorption enhancers to enhance the despersibility of spray-dried powders for pulmonary gene therapy. / Li, Hao-Ying; Seville, Peter C.; Williamson, I.J.; Birchall, J.C.

In: Journal of Gene Medicine, Vol. 7, No. 8, 08.2005, p. 1035-1043.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The use of absorption enhancers to enhance the despersibility of spray-dried powders for pulmonary gene therapy

AU - Li, Hao-Ying

AU - Seville, Peter C.

AU - Williamson, I.J.

AU - Birchall, J.C.

PY - 2005/8

Y1 - 2005/8

N2 - Background: Pulmonary gene therapy requires aerosolisation of the gene vectors to the target region of the lower respiratory tract. Pulmonary absorption enhancers have been shown to improve the penetration of pharmaceutically active ingredients in the airway. In this study, we investigate whether certain absorption enhancers may also enhance the aerosolisation properties of spray-dried powders containing non-viral gene vectors. Methods: Spray-drying was used to prepare potentially respirable trehalose-based dry powders containing lipid-polycation-pDNA (LPD) vectors and absorption enhancers. Powder morphology and particle size were characterised using scanning electron microscopy and laser diffraction, respectively, with gel electrophoresis used to assess the structural integrity of the pDNA. The biological functionality of the powders was quantified using in vitro cell (A549) transfection. Aerosolisation from a Spinhaler® dry powder inhaler into a multistage liquid impinger (MSLI) was used to assess the in vitro dispersibility and deposition of the powders. Results: Spray-dried powder containing dimethyl-β-cyclodextrin (DMC) demonstrated substantially altered particle morphology and an optimal particle size distribution for pulmonary delivery. The inclusion of DMC did not adversely affect the structural integrity of the LPD complex and the powder displayed significantly greater transfection efficiency as compared to unmodified powder. All absorption enhancers proffered enhanced powder deposition characteristics, with the DMC-modified powder facilitating high deposition in the lower stages of the MSLI. Conclusions: Incorporation of absorption enhancers into non-viral gene therapy formulations prior to spray-drying can significantly enhance the aerosolisation properties of the resultant powder and increase biological functionality at the site of deposition in an in vitro model. Copyright © 2005 John Wiley & Sons, Ltd.

AB - Background: Pulmonary gene therapy requires aerosolisation of the gene vectors to the target region of the lower respiratory tract. Pulmonary absorption enhancers have been shown to improve the penetration of pharmaceutically active ingredients in the airway. In this study, we investigate whether certain absorption enhancers may also enhance the aerosolisation properties of spray-dried powders containing non-viral gene vectors. Methods: Spray-drying was used to prepare potentially respirable trehalose-based dry powders containing lipid-polycation-pDNA (LPD) vectors and absorption enhancers. Powder morphology and particle size were characterised using scanning electron microscopy and laser diffraction, respectively, with gel electrophoresis used to assess the structural integrity of the pDNA. The biological functionality of the powders was quantified using in vitro cell (A549) transfection. Aerosolisation from a Spinhaler® dry powder inhaler into a multistage liquid impinger (MSLI) was used to assess the in vitro dispersibility and deposition of the powders. Results: Spray-dried powder containing dimethyl-β-cyclodextrin (DMC) demonstrated substantially altered particle morphology and an optimal particle size distribution for pulmonary delivery. The inclusion of DMC did not adversely affect the structural integrity of the LPD complex and the powder displayed significantly greater transfection efficiency as compared to unmodified powder. All absorption enhancers proffered enhanced powder deposition characteristics, with the DMC-modified powder facilitating high deposition in the lower stages of the MSLI. Conclusions: Incorporation of absorption enhancers into non-viral gene therapy formulations prior to spray-drying can significantly enhance the aerosolisation properties of the resultant powder and increase biological functionality at the site of deposition in an in vitro model. Copyright © 2005 John Wiley & Sons, Ltd.

KW - absorption enhancer

KW - deposition

KW - gene delivery

KW - lung

KW - non-viral

KW - spray drying

UR - http://www.scopus.com/inward/record.url?scp=23944455043&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1002/jgm.749/abstract

U2 - 10.1002/jgm.749

DO - 10.1002/jgm.749

M3 - Article

VL - 7

SP - 1035

EP - 1043

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 8

ER -